CA2238875A1 - Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv - Google Patents

Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv

Info

Publication number
CA2238875A1
CA2238875A1 CA002238875A CA2238875A CA2238875A1 CA 2238875 A1 CA2238875 A1 CA 2238875A1 CA 002238875 A CA002238875 A CA 002238875A CA 2238875 A CA2238875 A CA 2238875A CA 2238875 A1 CA2238875 A1 CA 2238875A1
Authority
CA
Canada
Prior art keywords
pde
tri
inhibitors
ethane derivatives
aryl ethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002238875A
Other languages
English (en)
Other versions
CA2238875C (fr
Inventor
Daniel Guay
Yves Girard
Yves Ducharme
Marc Blouin
Pierre Hamel
Mario Girard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606377.1A external-priority patent/GB9606377D0/en
Application filed by Individual filed Critical Individual
Publication of CA2238875A1 publication Critical patent/CA2238875A1/fr
Application granted granted Critical
Publication of CA2238875C publication Critical patent/CA2238875C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA002238875A 1995-12-15 1996-12-11 Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv Expired - Fee Related CA2238875C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US870495P 1995-12-15 1995-12-15
US60/008,704 1995-12-15
GBGB9606377.1A GB9606377D0 (en) 1996-03-26 1996-03-26 Tri-aryl ethane derivatives as PDE IV inhibitors
GB9606377.1 1996-03-26
PCT/CA1996/000839 WO1997022586A1 (fr) 1995-12-15 1996-12-11 Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv

Publications (2)

Publication Number Publication Date
CA2238875A1 true CA2238875A1 (fr) 1997-06-26
CA2238875C CA2238875C (fr) 2003-09-16

Family

ID=26308993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002238875A Expired - Fee Related CA2238875C (fr) 1995-12-15 1996-12-11 Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv

Country Status (5)

Country Link
EP (1) EP0873311A1 (fr)
JP (1) JP3465825B2 (fr)
AU (1) AU707574B2 (fr)
CA (1) CA2238875C (fr)
WO (1) WO1997022586A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000359A1 (fr) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Derives de noyau aromatique
RU2235095C2 (ru) 1998-10-06 2004-08-27 Дайниппон Фармасьютикал Ко., Лтд. 2,3-дизамещенное производное пиридина, способы его получения, содержащая его фармацевтическая композиция и промежуточный продукт для его получения
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
PT1212089E (pt) 1999-08-21 2006-08-31 Altana Pharma Ag Combinacao sinergica de roflumilast e salmeterol
AU2002229611A1 (en) * 2000-12-08 2002-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
MXPA03010679A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
CA2447618A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Composition pour le traitement regeneratif de la maladie du cartilage
EP1569908B1 (fr) * 2002-11-19 2010-09-15 Memory Pharmaceuticals Corporation Pyridines N-Oxyde comme iNHIBITEURS DE LA PHOSPHODIESTERASE 4
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2017173274A1 (fr) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
RS62670B1 (sr) 2016-09-30 2021-12-31 Vertex Pharma Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora
MX2019006637A (es) 2016-12-09 2019-08-21 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
CA3071278A1 (fr) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Procedes de preparation de composes de pyrrolidine
CA3078893A1 (fr) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Formes cristallines et compositions de modulateurs de cftr
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (fr) 2018-04-13 2019-10-17 Alexander Russell Abela Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (fr) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation

Also Published As

Publication number Publication date
JP3465825B2 (ja) 2003-11-10
EP0873311A1 (fr) 1998-10-28
WO1997022586A1 (fr) 1997-06-26
CA2238875C (fr) 2003-09-16
AU707574B2 (en) 1999-07-15
JP2000501742A (ja) 2000-02-15
AU1028097A (en) 1997-07-14

Similar Documents

Publication Publication Date Title
CA2238875A1 (fr) Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv
MY132642A (en) Naphthyridine derivatives
WO2005037825A3 (fr) Inhibiteurs de la proteine kinase
EP1070710A3 (fr) Dérivés de dithiolane, leur préparation et leur action thérapeutique
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
EA200500376A1 (ru) Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf)
WO2000068198A3 (fr) Derives de pyridine heterosubstitues utilises comme inhibiteurs de pde 4
PL306084A1 (en) Novel compound and method of obtaining them as well as pharmaceutic agent containing such compounds
WO2001087882A3 (fr) Derives de pyrrolopyridinone substitues utiles en tant qu'inhibiteurs de la phosphodiesterase
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
CA2258548A1 (fr) Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
GB0004888D0 (en) Chemical compounds
WO2004026863A8 (fr) Nouveaux composes de triazole et d'oxazole, inhibiteurs du facteur de croissance transformant
WO2003048164A3 (fr) Antagonistes du recepteur a2a de l'adenosine
ATE316083T1 (de) Adamantanderivate
AU2001245972A1 (en) N-heterocyclic derivatives as nos inhibitors
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
WO2000064874A3 (fr) DERIVES DE PYRIDINE HETEROSUBSTITUES INHIBITEURS DE $i(PDE 4)
WO2004026306A3 (fr) Nouveaux composes de pyrazole utilises comme inhibiteurs du facteur de croissance transformant (tgf)
DE60005501D1 (de) 4'-c-ethynyl-pyrimidine nukleoside
WO2004100865A3 (fr) Nouveaux derives de benzimidazole
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed